Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, Monique C Minnema, Rui Bergantim, Roman Hájek, Cristina João, M Teresa Cibeira, Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Meletios A Dimopoulos, Sriram Ravichandran, Ute Hegenbart, Hermine Agis, Blanca Gros, Aisha Asra, Valeria Magarotto, Giorgos Cheliotis, Giorgos Psarros, Pieter Sonneveld, Ashutosh Wechalekar, Efstathios Kastritis
OBJECTIVES: To report healthcare resource utilization (HCRU) and safety outcomes in systemic light chain (AL) amyloidosis from the EMN23 study. MATERIALS AND METHODS: The retrospective, observational, multinational EMN23 study included 4,480 patients initiating first-line treatment for AL amyloidosis in 2004-2018 and assessed, among other objectives, HCRU and safety outcomes. HCRU included hospitalizations, examinations, and dialysis; safety included serious adverse events (SAEs) and adverse events of special interest (AESIs)...
February 1, 2024: Clinical Lymphoma, Myeloma & Leukemia